Product Images Levetiracetam

This is a medication called Levetiracetam in the form of tablets with each tablet containing 750 mg of the medication. The medication is to be used as directed and the package insert should be consulted. It is repackaged by a company called RemedyRepack Inc. and manufactured by Lupin Pharma in Baltimore. The NDC number for this medication is 70518-1827-00 and the lot number and expiry date should be available on the packaging. This medication should be stored at 20-25°C and kept away from children.*

This text is a simple formula that calculates the total daily dose of a medication based on the patient's weight and a given daily dose in milligrams per kilogram. The formula multiplies the daily dose (mg/kg/day) by the patient's weight (in kg) and then divides by 100 mg/mL to get the total daily dose in milliliters.*

This text appears to be describing a formula used to calculate a patient's renal clearance (CLer), which is adjusted for body surface area (BSA). The formula involves multiplying 140 minus the patient's age (in years) by their weight (in kilograms) and dividing the result by 72 times their serum creatinine level (in milligrams per deciliter), with an adjustment factor of 0.85 for female patients. Then, to adjust for BSA, a conversion factor of 1.73 is used, dividing the original CLer value by the subject's BSA (in square meters).*

This appears to be a graph or chart displaying percentages, with labels indicating different doses of Levetiracetam. Without additional context, it is not clear what the graph is measuring or intended to communicate.*

This appears to be a graph or table showing the percentages of patients at different dosages (1000 mg/day and 2000 mg/day) of the drug Levetiracetam compared to a placebo. However, without further context or labels, it is difficult to interpret the significance of the percentages.*

This data appears to show the percentage of patients in a study, divided by treatment group (placebo vs. levetiracetam). However, without further context or information it is difficult to determine the purpose or outcome of the study.*

This is a summary of the percentage of patients taking placebo and levetiracetam (anti-seizure medication) in a study. 19.6% of 51 patients took placebo, while 43.1% of 58 patients took levetiracetam.*

This is a chart representing the percentage of patients who fall under certain categories. Unfortunately, the categories are not described, so the content of the chart is not-available.*